{"id":"NCT00380250","sponsor":"Sucampo Pharma Americas, LLC","briefTitle":"Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation","officialTitle":"Phase 3, 12-Week, Multicenter, Double-Blind, Randomized, Efficacy and Safety Study of Lubiprostone for the Treatment of Irritable Bowel Syndrome With Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":null,"completion":"2006-07","firstPosted":"2006-09-25","resultsPosted":"2014-02-11","lastUpdate":"2019-11-15"},"enrollment":590,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Irritable Bowel Syndrome With Constipation"],"interventions":[{"type":"DRUG","name":"Lubiprostone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lubiprostone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.","primaryOutcome":{"measure":"Overall Responder Rate","timeFrame":"12 weeks","effectByArm":[{"arm":"Lubiprostone Study Period I","deltaMin":13.8,"sd":null},{"arm":"Placebo Study Period I","deltaMin":7.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.029"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19006537"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":396},"commonTop":["Nausea","Diarrhoea","Abdominal Pain"]}}